TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01252992

Intervention type: GENETIC
Intervention: Genetic analysis
Description: 1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: 1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction.

Intervention type: RADIATION
Intervention: Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM
Description: at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist

Intervention type: RADIATION
Intervention: Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM
Description: at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist

Intervention type: OTHER
Intervention: Immunologic analysis
Description: For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+

Intervention type: OTHER
Intervention: Immunologic analysis
Description: For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+

Intervention type: OTHER
Intervention: QuantiferonTB Gold test
Description: at M0, M2, M6 and in case of PR+.
Study: NCT03365232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom base attachment
Description: custom base attachment
Study: NCT02433444

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: ERCP's performed at Cedars-Sinai Medical Center.
Study: NCT01156454

Intervention type: PROCEDURE
Intervention: X-ray
Description: surgical specimen taken to radiology and contents x-rayed
Study: NCT01562184

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS device
Description: Sham tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix tDCS device
Description: Active tDCS
Study: NCT00667732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5mcg twice a day, increasing to 10mcg twice a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5mcg twice a day, increased to 10mcg twice a day for 24 weeks
Study: NCT01522014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head
Study: NCT02123940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound score
Description: Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy

Intervention type: DEVICE
Group type: OTHER
Intervention: lung ultrasound score
Description: Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
Study: NCT03890484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Type - New Peer
Description: Participants drink with 2 unfamiliar confederate peers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Type - Close Friends
Description: Participants drink with 2 close friends
Study: NCT01314066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
Study: NCT04012905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids for Systemic Use
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Study: NCT01930669

Intervention type: OTHER
Group type: OTHER
Intervention: Gravitational sympathetic stimulus
Description: Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique.
Study: NCT00672139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Study: NCT00135408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab+ Placebo
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab+ Budesonide
Description: Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
Study: NCT01089933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block (TPVB)
Description: The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
Study: NCT00278486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation.
Description: Autologous hematopoietic stem cell transplantation will be performed.
Study: NCT03233308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: 1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
Study: NCT04605068

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse preputial island flap (Duckett's technique)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-faced preputial flap (DFPF)
Study: NCT04002206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretch
Description: Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
Study: NCT01240772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: doppler-guided arterial ligation with mucopexy
Description: doppler-guided arterial ligation with mucopexy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stapled haemorrhoidopexy according to Longo
Description: stapled haemorrhoidopexy according to Longo
Study: NCT03698214

Intervention type: OTHER
Intervention: reversed shock index < 1
Description: Among patients with isolated TBI, those with an RSI \< 1 had higher mortality

Intervention type: OTHER
Intervention: reversed shock index ≥ 1
Description: Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
Study: NCT03224832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery-first Approach
Description: Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas.
Study: NCT03224832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Approach
Description: In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
Study: NCT00498706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT)
Description: Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
Study: NCT04012905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids for Systemic Use
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Study: NCT00518206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 ISCOMATRIX® vaccine
Description: NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 ISCOMATRIX® vaccine
Description: NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Study: NCT03075878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.
Study: NCT03480815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal Temperature Controlled Laminar Flow Device
Description: Record of the time to first asthma exacerbation, lung function and exhaled NO level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None Device
Description: Record of the time to first asthma exacerbation, lung function and exhaled NO level
Study: NCT05643222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red tint contact lenses
Description: to compare the performance of these lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red tint contact lenses
Description: to compare the performance of these lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red tint contact lenses
Description: to compare the performance of these lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red tint contact lenses
Description: to compare the performance of these lenses.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study: NCT02477735

Intervention type: DEVICE
Intervention: Actigraphy
Description: Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
Study: NCT03454269

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Study: NCT00498706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face administered CBT (FtF-CBT)
Description: Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
Study: NCT00794989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground Flaxseed
Description: Given orally

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants randomized to Arm 2 do not receive any intervention
Study: NCT02889679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater resection
Description: Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (gas distended colon) resection
Description: Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study: NCT02889679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard polypectomy
Description: Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard polypectomy
Description: Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
Study: NCT03625037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Administered as specified in the treatment arm.
Study: NCT03833089

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Targeted serum potassium level
Description: In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,